Exousia Pro Has Appointed Matthew Dwyer As Its New President
Marijuana Inc. (OTC PINK:MAJI), operating as Exousia Pro, has appointed Matthew Dwyer as its new President. Dwyer brings 37 years of market experience, specializing in OTC markets and SEC procedures. He currently co-owns a brokerage firm and has maintained a clean regulatory record throughout his career.
Dwyer's appointment comes with a performance-based compensation package, including shares and cash bonus upon completing key objectives: company audit, advisory board creation, SEC share registration, OTCQB uplisting, revenue generation through organic growth and acquisitions, and securing investment banking relationships.
The company, a clinical-stage biotech focusing on exosome treatments for cancer and other conditions, aims to advance its glioblastoma therapeutic and commercialize exosome technology. CEO Mike Sheikh emphasized Dwyer's regulatory expertise as important for achieving fully reporting status while avoiding toxic financing structures.
Marijuana Inc. (OTC PINK:MAJI), operante come Exousia Pro, ha nominato Matthew Dwyer come nuovo Presidente. Dwyer porta con sé 37 anni di esperienza nel mercato, specializzandosi nei mercati OTC e nelle procedure della SEC. Attualmente è co-proprietario di una società di intermediazione e ha mantenuto un record normativo impeccabile durante la sua carriera.
La nomina di Dwyer è accompagnata da un pacchetto retributivo basato sulle performance, che include azioni e un bonus in contante al raggiungimento di obiettivi chiave: audit aziendale, creazione di un consiglio consultivo, registrazione delle azioni presso la SEC, uplisting OTCQB, generazione di entrate attraverso crescita organica e acquisizioni, e consolidamento di relazioni con banche d'investimento.
L'azienda, una biotech in fase clinica focalizzata sui trattamenti con esosomi per il cancro e altre condizioni, punta a far avanzare la sua terapia per il glioblastoma e commercializzare la tecnologia degli esosomi. Il CEO Mike Sheikh ha sottolineato l'esperienza normativa di Dwyer come fondamentale per raggiungere lo status di reporting completo, evitando strutture di finanziamento tossiche.
Marijuana Inc. (OTC PINK:MAJI), que opera como Exousia Pro, ha nombrado a Matthew Dwyer como su nuevo Presidente. Dwyer aporta 37 años de experiencia en el mercado, especializándose en mercados OTC y procedimientos de la SEC. Actualmente es co-propietario de una firma de corretaje y ha mantenido un historial regulatorio limpio a lo largo de su carrera.
El nombramiento de Dwyer viene con un paquete de compensación basado en el rendimiento, que incluye acciones y un bono en efectivo al completar objetivos clave: auditoría de la empresa, creación de un consejo asesor, registro de acciones en la SEC, uplisting en OTCQB, generación de ingresos a través del crecimiento orgánico y adquisiciones, y aseguramiento de relaciones con bancos de inversión.
La empresa, una biotecnológica en etapa clínica centrada en tratamientos con exosomas para el cáncer y otras condiciones, tiene como objetivo avanzar en su terapia para glioblastoma y comercializar la tecnología de exosomas. El CEO Mike Sheikh enfatizó la experiencia regulatoria de Dwyer como importante para lograr el estatus de reporte completo, evitando estructuras de financiamiento tóxicas.
Marijuana Inc. (OTC PINK:MAJI), Exousia Pro로 운영되며, Matthew Dwyer를 새로운 사장으로 임명했습니다. Dwyer는 OTC 시장 및 SEC 절차를 전문으로 하는 37년의 시장 경험을 가지고 있습니다. 현재 그는 중개 회사의 공동 소유주이며 경력 동안 깨끗한 규제 기록을 유지해왔습니다.
Dwyer의 임명은 성과 기반 보상 패키지와 함께 제공되며, 주요 목표를 완료할 때 주식과 현금 보너스가 포함됩니다: 회사 감사, 자문 위원회 구성, SEC 주식 등록, OTCQB 상장, 유기적 성장 및 인수를 통한 수익 창출, 투자은행 관계 확보.
이 회사는 암 및 기타 질환에 대한 엑소좀 치료에 중점을 둔 임상 단계의 생명공학 회사로, 교모세포종 치료제를 발전시키고 엑소좀 기술을 상용화하는 것을 목표로 하고 있습니다. CEO Mike Sheikh는 Dwyer의 규제 전문성이 완전 보고 상태를 달성하고 독성 금융 구조를 피하는 데 중요하다고 강조했습니다.
Marijuana Inc. (OTC PINK:MAJI), opérant sous le nom de Exousia Pro, a nommé Matthew Dwyer comme nouveau Président. Dwyer apporte 37 ans d'expérience sur le marché, se spécialisant dans les marchés OTC et les procédures de la SEC. Il est actuellement copropriétaire d'une société de courtage et a maintenu un dossier réglementaire impeccable tout au long de sa carrière.
La nomination de Dwyer s'accompagne d'un package de rémunération basé sur la performance, comprenant des actions et un bonus en espèces à l'achèvement d'objectifs clés : audit de l'entreprise, création d'un conseil consultatif, enregistrement des actions auprès de la SEC, uplisting OTCQB, génération de revenus par croissance organique et acquisitions, et sécurisation de relations avec des banques d'investissement.
L'entreprise, une biotech en phase clinique axée sur les traitements par exosomes pour le cancer et d'autres conditions, vise à faire avancer sa thérapie pour le glioblastome et à commercialiser la technologie des exosomes. Le PDG Mike Sheikh a souligné l'expertise réglementaire de Dwyer comme étant essentielle pour atteindre le statut de rapport complet tout en évitant des structures de financement toxiques.
Marijuana Inc. (OTC PINK:MAJI), das als Exousia Pro agiert, hat Matthew Dwyer zu seinem neuen Präsidenten ernannt. Dwyer bringt 37 Jahre Markterfahrung mit, spezialisiert auf OTC-Märkte und SEC-Verfahren. Derzeit ist er Mitinhaber eines Maklerunternehmens und hat während seiner Karriere einen sauberen regulatorischen Rekord beibehalten.
Die Ernennung von Dwyer erfolgt mit einem leistungsbasierten Vergütungspaket, das Aktien und einen Barbonus bei Erfüllung wichtiger Ziele umfasst: Unternehmensprüfung, Gründung eines Beratungsgremiums, SEC-Aktienregistrierung, OTCQB-Listung, Umsatzgenerierung durch organisches Wachstum und Übernahmen sowie Sicherstellung von Beziehungen zu Investmentbanken.
Das Unternehmen, ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Exosombehandlungen für Krebs und andere Erkrankungen konzentriert, hat das Ziel, seine Therapie für Glioblastom voranzutreiben und die Exosomtechnologie zu kommerzialisieren. CEO Mike Sheikh betonte Dwyers regulatorische Expertise als wichtig, um den Status der vollständigen Berichterstattung zu erreichen und toxische Finanzierungsstrukturen zu vermeiden.
- Appointment of experienced President with 37 years of market expertise and clean regulatory record
- Strategic plan for uplisting to OTCQB status
- Performance-based compensation structure aligns with shareholder interests
- Clear focus on avoiding toxic financing structures
- No immediate revenue generation
- Clinical-stage status indicates pre-revenue phase
- Potential future share dilution from President's compensation package
ORLANDO, FL / ACCESS Newswire / April 2, 2025 / MARIJUANA INC. (OTC PINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company using exosomes in the treatment of cancer and other maladies, is pleased to announce the appointment of Matthew Dwyer to serve as President of the Company.
Mr. Dwyer will serve as President only and will not be a member of the Board. Mr. Dwyer brings over 37 years of market experience and is considered an expert in the OTC market. Mr. Dwyer possesses extensive knowledge of the procedures and processes required to navigate the OTC and the SEC. Mr. Dwyer has held several financial licenses throughout his 37-year career and is currently a part-owner of an active brokerage firm. During his 37 years, Mr. Dwyer has never had any complaints or regulatory issues. Mr. Dwyer has held the position of officer and director in numerous public companies and continues to work as a consultant and financier to several companies, including MAJI.
Mr. Dwyer currently holds no shares of MAJI or has held any; he has agreed to a back-end compensation package. Should he complete all the tasks assigned to him, he will receive shares of the Company and a cash bonus. The following is a list of the tasks assigned:
Audit the Company
Create an Advisory Board
Complete an SEC filing to register the shares
Complete an uplist to OTCQB
Drive revenue into the Company organically and through acquisitions
Find an investment banker to take the Company to the next level
"When I first looked at this deal as a consultant, I realized that out of all the deals I've seen in my career, this one was special," said Matthew Dwyer, President of Exousia Pro, Inc. "I saw the potential to really build a biotech, and didn't want to be on the outside looking in, which is why I'm so grateful for the opportunity to serve shareholders. My strength in operations and fundraising will keep the company's financial compliance on track and I'm extremely focused in supporting our CEO in our strategy to commercialize exosomes and advance our therapeutic in glioblastoma."
"I have personally known and worked with Matthew since 2016," stated Mike Sheikh, CEO of Exousia Pro, Inc. "I have firsthand experience working with him, and I appreciate his knowledge of the industry. His regulatory knowledge is invaluable as we move toward a fully reporting status and beyond. I look forward to collaborating with him as we grow Exousia Pro putting shareholders first and steering clear of any toxic financing structures."
About us
Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology.The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Marijuana, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
ir@exousiapro.com
SOURCE: Marijuana Inc.
View the original press release on ACCESS Newswire
FAQ
What are Matthew Dwyer's main objectives as the new President of MAJI?
What is the compensation structure for MAJI's new President Matthew Dwyer?
How will MAJI benefit from Matthew Dwyer's experience in the OTC markets?
What are MAJI's current development focus areas in biotechnology?
